Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.

Antiviral research - 1 Jan 2018

Mandour Mohamed, Vliegen Inge, Paeshuyse Jan, Neyts Johan

Abstract excerpt

Combination therapy of directly acting antivirals (DAA's) for the treatment of chronic HCV infections has proven to be a highly effective strategy to cure chronic infections with this virus. Here we studied, using HCV as an example, how to best design in vitro studies that explore the combined antiviral efficiency of combinations of three or more DAA's. To that end we used a HCV NS3 protease inhibitor, a NS5A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Design
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Viral

Share to Hepatitis C

Share to In Vitro Techniques

Share to Viral Load

Share to Virus Replication

Source

Identifiers

PMID: 29154807
DOI: 10.1016/j.antiviral.2017.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.PMID 29154807Read ↗

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Semantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infection.Semantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

Required concentration index quantifies effective drug combinations against hepatitis C virus infectionSemantic proximity Read ↗

New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.Semantic proximity Read ↗

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.Semantic proximity Read ↗

Synergistic Antiviral Activity of Human Interferon Combinations in the Hepatitis C Virus Replicon SystemSemantic proximity Read ↗

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.Semantic proximity Read ↗

Selecting and characterizing drug-resistant hepatitis C virus replicon.Semantic proximity Read ↗

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesSemantic proximity Read ↗

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Semantic proximity Read ↗

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.